Oncology KB
Home/Colorectal Cancer
Loading filters...
Publications per Year (4915 total)
22
1990
27
·
25
·
23
·
41
·
45
1995
43
·
42
·
44
·
55
·
46
2000
68
·
63
·
87
·
65
·
117
2005
136
·
127
·
123
·
148
·
141
2010
174
·
174
·
201
·
217
·
203
2015
196
·
209
·
207
·
201
·
221
2020
242
·
241
·
269
·
272
·
257
2025
143
·
Loaded
Click to load
50 / 4915 papers loaded(scroll for more)

202650 papers

MSI-H/dMMRAdvanced/Metastatic (IV)2026

Revised Tumor Burden Score for Prognostic Stratification in Metastatic Colorectal Cancer Patients Receiving Immunotherapy: A Retrospective Study.

Zhang YY et al. Oncologist. 2026

GeneralEarly (I-III)2026

Impact of Obesity on Postoperative Outcomes in Transanal Total Mesorectal Excision for Rectal Cancer.

Zewde MG et al. Dis Colon Rectum. 2026

GeneralAdvanced/Metastatic (IV)2026

Drink Responsibly: Cancer Cells Also Like Sugary Drinks.

Zani F et al. Cancer Res. 2026

MSI-H/dMMRAdvanced/Metastatic (IV)2026

Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.

Yeh C et al. Clin Cancer Res. 2026

MSI-H/dMMREarly (I-III)2026

Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer.

Yang Z et al. Gut. 2026

GeneralAdvanced/Metastatic (IV)2026

Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.

Liu X et al. ESMO Open. 2026

MSI-H/dMMRAll Stages2026

Dual mechanism of immune escape shapes the genetic and immunogenic landscape of mismatch repair-deficient colorectal tumours.

Xavier-Ferreira H et al. Gut. 2026

GeneralAll Stages2026

Oxaliplatin-induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose-response relationship and impact on quality of life.

Wurschi GW et al. Int J Cancer. 2026

GeneralAll Stages2026

The perioperative microbiome of patients undergoing rectal cancer surgery: A pilot study.

Wienholts K et al. Colorectal Dis. 2026

GeneralEarly (I-III)2026

Treatment Adequacy and Baseline Risk Modify the Association Between Adjuvant Chemotherapy and Survival After Pathological Complete Response in Rectal Cancer.

Wang C et al. Int J Cancer. 2026

GeneralAll Stages2026

Exosomal miRNA Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer.

Wada Y et al. Dis Colon Rectum. 2026

GeneralEarly (I-III)2026

Cost-Effectiveness of Pelvic Floor Reconstruction Using Biological Mesh After Extralevator Abdominoperineal resection for Rectal Cancer.

van den Berg R et al. Dis Colon Rectum. 2026

GeneralAdvanced/Metastatic (IV)2026

Third-line treatment decision-making for metastatic colorectal cancer: a cross-sectional survey of US community physicians.

Cann C et al. Oncologist. 2026

GeneralAll Stages2026

A standardised approach to the pathological dissection and reporting of pelvic exenteration specimens: Recommendations from the UK Pelvic Exenteration Network (UKPEN).

Aldridge J et al. Colorectal Dis. 2026

GeneralAll Stages2026

Laparoscopic Sacrectomy as Part of En Bloc Resection for Locally Recurrent Rectal Cancer.

Uemura M et al. Dis Colon Rectum. 2026

GeneralAll Stages2026

TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis.

Mödl B et al. Cancer Res. 2026

RAS wild-typeAll Stages2026

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

Fountzilas C et al. Int J Cancer. 2026

GeneralAll Stages2026

Development and validation of web-based prediction models for major low anterior resection syndrome at 3 and 6 months after sphincter-preserving surgery in patients with rectal cancer.

Sun L et al. Int J Colorectal Dis. 2026

GeneralEarly (I-III)2026

Gut microbiota-associated predictors as biomarkers of neoadjuvant treatment response in rectal cancer-a systematic review.

Stepanyan A et al. Br J Cancer. 2026

GeneralAdvanced/Metastatic (IV)2026

SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts.

Liu S et al. Cancer Res. 2026

Biomarker/ctDNAAll Stages2026

ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors.

Solé L et al. Br J Cancer. 2026

GeneralEarly (I-III)2026

Added value of adjuvant chemotherapy in patients with node-positive pT1-2 Colon cancer - A national SNAPSHOT analysis.

Hanevelt J et al. Oncologist. 2026

Biomarker/ctDNAEarly (I-III)2026

Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients.

Franken IA et al. Eur J Cancer. 2026

MSI-H/dMMRAdvanced/Metastatic (IV)2026

Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multi-Omics Platform.

Sinicrope FA et al. Clin Cancer Res. 2026

GeneralEarly (I-III)2026

Effect of prolonged interval between neoadjuvant chemoradiotherapy and surgery on pathological and oncological outcomes in locally advanced rectal cancer: a randomized controlled trial.

Sileika E et al. Int J Colorectal Dis. 2026

GeneralEarly (I-III)2026

Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy.

Shen Y et al. Clin Cancer Res. 2026

GeneralEarly (I-III)2026

Early evaluation of the low anterior resection syndrome after sphincter sparing rectal cancer surgery and prompt treatment: a cohort study protocol.

Sguinzi R et al. Int J Colorectal Dis. 2026

GeneralEarly (I-III)2026

Long-term outcomes of pT1 rectal cancer after transanal endoscopic surgery: again, a word of caution on high local recurrence - a cohort study.

Serra-Aracil X et al. Int J Colorectal Dis. 2026

GeneralEarly (I-III)2026

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Iveson T et al. J Clin Oncol. 2026

Biomarker/ctDNAAll Stages2026

New prognostic and predictive scoring systems for colorectal cancer liver metastases.

Salvà F et al. ESMO Open. 2026

GeneralAdvanced/Metastatic (IV)2026

Young adults undergoing anterior resection for colorectal cancer experience fewer medical complications but a comparable risk of anastomotic leak.

Rudasill SE et al. Colorectal Dis. 2026

GeneralEarly (I-III)2026

Living 20 years with perineal colostomy and dynamic graciloplasty - a case report discussing the role of this approach.

Rosen H et al. Int J Colorectal Dis. 2026

Biomarker/ctDNAAdvanced/Metastatic (IV)2026

Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors.

Ros J et al. ESMO Open. 2026

GeneralEarly (I-III)2026

Rectal Cancer in the Elderly: To Operate or Not to Operate? A Nationwide Retrospective Study of the Italian Society of Surgical Oncology-Colorectal Cancer Network Collaborative Group.

Reddavid R et al. Dis Colon Rectum. 2026

RAS wild-typeAdvanced/Metastatic (IV)2026

ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial.

Manca P et al. Clin Cancer Res. 2026

RAS wild-typeAdvanced/Metastatic (IV)2026

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.

Potthoff K et al. Int J Cancer. 2026

BRAF V600EAdvanced/Metastatic (IV)2026

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.

Ciracì P et al. Ann Oncol. 2026

MSI-H/dMMRAdvanced/Metastatic (IV)2026

Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.

Salem ME et al. Clin Cancer Res. 2026

GeneralAdvanced/Metastatic (IV)2026

Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases.

Rajtmajerova M et al. Int J Cancer. 2026

GeneralEarly (I-III)2026

Deep impact analysis of surgical strategy changes guided by indocyanine green fluorescence angiography in laparoscopic low anterior resection for rectal cancer.

Qiu X et al. Int J Colorectal Dis. 2026

Biomarker/ctDNAAdvanced/Metastatic (IV)2026

Noninvasive diagnosis of colorectal adenoma: The emerging potential of blood-based biomarkers.

Qi CY et al. World J Gastroenterol. 2026

MSI-H/dMMREarly (I-III)2026

Bifidobacterium catenulatum boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8+ T cells.

Li X et al. Gut. 2026

GeneralEarly (I-III)2026

Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers.

Noiret B et al. J Clin Oncol. 2026

GeneralAdvanced/Metastatic (IV)2026

eIF3i facilitates NELFCD translation to promote metastasis via regulating EMT and invadopodia.

Huang Q et al. Br J Cancer. 2026

MSI-H/dMMRAdvanced/Metastatic (IV)2026

Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.

Nasca V et al. Oncologist. 2026

MSI-H/dMMRAll Stages2026

Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy.

Iglesias Coma M et al. Gut. 2026

GeneralAll Stages2026

Clinical utility of longitudinal ctDNA monitoring by multiplex MS-ddPCR for risk stratification and follow-up in rectal cancer.

Lauridsen ED et al. Int J Colorectal Dis. 2026

MSI-H/dMMRAll Stages2026

Evaluating MRI response criteria in microsatellite instability-high rectal cancer treated with immune checkpoint inhibitors.

Vanderbecq Q et al. ESMO Open. 2026

GeneralAll Stages2026

An interpretable machine learning model based on MRI radiomics and GAME score for predicting early recurrence after thermal ablation in colorectal liver metastases.

Kong Y et al. Int J Colorectal Dis. 2026

GeneralEarly (I-III)2026

The significance of MRI-detected lateral lymph node metastasis in rectal cancer on local recurrence and survival-A nationwide cohort study.

Agger E et al. Colorectal Dis. 2026